Ovarian Cancer
ICER’s report reviews evidence on the comparative clinical effectiveness and value of poly (ADP-ribose) polymerase (PARP) inhibitors for treatment of ovarian cancer. During the public meeting the Midwest CEPAC voted on key questions related to the clinical effectiveness and value of the PARP inhibitors in two key populations: women receiving maintenance therapy for recurrent disease that […]
Recent Comments